Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 2 boards, counting each seat separately. Longest: Myriad Genetics Inc., 3 years.
Myriad Genetics Inc.
Director
Illumina Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Illumina Inc. | Grant or award | +1,674 | $164.28 | $275,005 |
| Jun 4, 2026 | Myriad Genetics Inc. | Grant or award | +59,701 | — | — |
| Feb 9, 2026 | Eli Lilly and Company | Grant or award | +15,548 | $1,044.67 | $16,242,383 |
| Feb 1, 2026 | Eli Lilly and Company | Option exercise | +12,684 | — | — |
| Feb 1, 2026 | Eli Lilly and Company | Shares withheld for tax | −5,641 | $1,037.15 | $5,850,822 |
| Nov 10, 2025 | Eli Lilly and Company | Gift | −179 | — | — |
| Aug 12, 2025 | Eli Lilly and Company | Open-market purchase | +1,000 | $634.41 | $634,410 |
| Jun 5, 2025 | Myriad Genetics Inc. | Grant or award | +49,796 | — | — |
| Feb 10, 2025 | Eli Lilly and Company | Open-market sale | −3,950 | $862.69 | $3,407,626 |
| Feb 10, 2025 | Eli Lilly and Company | Open-market sale | −340 | $863.97 | $293,750 |
| Feb 10, 2025 | Eli Lilly and Company | Open-market sale | −710 | $865.76 | $614,690 |
| Feb 10, 2025 | Eli Lilly and Company | Grant or award | +18,772 | $868.88 | $16,310,398 |
| Feb 1, 2025 | Eli Lilly and Company | Option exercise | +8,989 | — | — |
| Feb 1, 2025 | Eli Lilly and Company | Shares withheld for tax | −4,004 | $811.08 | $3,247,272 |
| Sep 11, 2024 | Eli Lilly and Company | Gift | −5,724 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.